Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria

Kaori Hayashi, Hiroyuki Sasamura, Mari Nakamura, Yusuke Sakamaki, Tatsuhiko Azegami, Hideyo Oguchi, Hirobumi Tokuyama, Shu Wakino, Koichi Hayashi, Hiroshi Itoh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Proteinuria is a central component of chronic kidney disease and an independent risk factor for cardiovascular disease. Kidney podocytes have an essential role as a filtration barrier against proteinuria. Kruppel-like Factor 4 (KLF4) is expressed in podocytes and decreased in glomerular diseases leading to methylation of the nephrin promoter, decreased nephrin expression and proteinuria. Treatment with an angiotensin receptor blocker (ARB) reduced methylation of the nephrin promoter in murine glomeruli of an adriamycin nephropathy model with recovery of KLF4 expression and a decrease in albuminuria. In podocyte-specific KLF4 knockout mice, the effect of ARB on albuminuria and the nephrin promoter methylation was attenuated. In cultured human podocytes, angiotensin II reduced KLF4 expression and caused methylation of the nephrin promoter with decreased nephrin expression. In patients, nephrin promoter methylation was increased in proteinuric kidney diseases with decreased KLF4 and nephrin expression. KLF4 expression in ARB-treated patients was higher in patients with than without ARB treatment. Thus, angiotensin II can modulate epigenetic regulation in podocytes and ARB inhibits these actions in part via KLF4 in proteinuric kidney diseases. This study provides a new concept that renin-angiotensin system blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression.

Original languageEnglish
Pages (from-to)745-753
Number of pages9
JournalKidney International
Volume88
Issue number4
DOIs
Publication statusPublished - 2015 Oct 3

Fingerprint

Podocytes
Angiotensins
Proteinuria
Renin
Angiotensin Receptor Antagonists
Methylation
Albuminuria
Kidney Diseases
Epigenomics
Angiotensin II
Kidney
GKLF protein
nephrin
Therapeutic Uses
Renin-Angiotensin System
Chronic Renal Insufficiency
Knockout Mice
Doxorubicin
Cardiovascular Diseases
Gene Expression

Keywords

  • angiotensin
  • chronic kidney disease
  • proteinuria

ASJC Scopus subject areas

  • Nephrology

Cite this

Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria. / Hayashi, Kaori; Sasamura, Hiroyuki; Nakamura, Mari; Sakamaki, Yusuke; Azegami, Tatsuhiko; Oguchi, Hideyo; Tokuyama, Hirobumi; Wakino, Shu; Hayashi, Koichi; Itoh, Hiroshi.

In: Kidney International, Vol. 88, No. 4, 03.10.2015, p. 745-753.

Research output: Contribution to journalArticle

@article{1b38f4a0290c45e0845a05479a0689eb,
title = "Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria",
abstract = "Proteinuria is a central component of chronic kidney disease and an independent risk factor for cardiovascular disease. Kidney podocytes have an essential role as a filtration barrier against proteinuria. Kruppel-like Factor 4 (KLF4) is expressed in podocytes and decreased in glomerular diseases leading to methylation of the nephrin promoter, decreased nephrin expression and proteinuria. Treatment with an angiotensin receptor blocker (ARB) reduced methylation of the nephrin promoter in murine glomeruli of an adriamycin nephropathy model with recovery of KLF4 expression and a decrease in albuminuria. In podocyte-specific KLF4 knockout mice, the effect of ARB on albuminuria and the nephrin promoter methylation was attenuated. In cultured human podocytes, angiotensin II reduced KLF4 expression and caused methylation of the nephrin promoter with decreased nephrin expression. In patients, nephrin promoter methylation was increased in proteinuric kidney diseases with decreased KLF4 and nephrin expression. KLF4 expression in ARB-treated patients was higher in patients with than without ARB treatment. Thus, angiotensin II can modulate epigenetic regulation in podocytes and ARB inhibits these actions in part via KLF4 in proteinuric kidney diseases. This study provides a new concept that renin-angiotensin system blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression.",
keywords = "angiotensin, chronic kidney disease, proteinuria",
author = "Kaori Hayashi and Hiroyuki Sasamura and Mari Nakamura and Yusuke Sakamaki and Tatsuhiko Azegami and Hideyo Oguchi and Hirobumi Tokuyama and Shu Wakino and Koichi Hayashi and Hiroshi Itoh",
year = "2015",
month = "10",
day = "3",
doi = "10.1038/ki.2015.178",
language = "English",
volume = "88",
pages = "745--753",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria

AU - Hayashi, Kaori

AU - Sasamura, Hiroyuki

AU - Nakamura, Mari

AU - Sakamaki, Yusuke

AU - Azegami, Tatsuhiko

AU - Oguchi, Hideyo

AU - Tokuyama, Hirobumi

AU - Wakino, Shu

AU - Hayashi, Koichi

AU - Itoh, Hiroshi

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Proteinuria is a central component of chronic kidney disease and an independent risk factor for cardiovascular disease. Kidney podocytes have an essential role as a filtration barrier against proteinuria. Kruppel-like Factor 4 (KLF4) is expressed in podocytes and decreased in glomerular diseases leading to methylation of the nephrin promoter, decreased nephrin expression and proteinuria. Treatment with an angiotensin receptor blocker (ARB) reduced methylation of the nephrin promoter in murine glomeruli of an adriamycin nephropathy model with recovery of KLF4 expression and a decrease in albuminuria. In podocyte-specific KLF4 knockout mice, the effect of ARB on albuminuria and the nephrin promoter methylation was attenuated. In cultured human podocytes, angiotensin II reduced KLF4 expression and caused methylation of the nephrin promoter with decreased nephrin expression. In patients, nephrin promoter methylation was increased in proteinuric kidney diseases with decreased KLF4 and nephrin expression. KLF4 expression in ARB-treated patients was higher in patients with than without ARB treatment. Thus, angiotensin II can modulate epigenetic regulation in podocytes and ARB inhibits these actions in part via KLF4 in proteinuric kidney diseases. This study provides a new concept that renin-angiotensin system blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression.

AB - Proteinuria is a central component of chronic kidney disease and an independent risk factor for cardiovascular disease. Kidney podocytes have an essential role as a filtration barrier against proteinuria. Kruppel-like Factor 4 (KLF4) is expressed in podocytes and decreased in glomerular diseases leading to methylation of the nephrin promoter, decreased nephrin expression and proteinuria. Treatment with an angiotensin receptor blocker (ARB) reduced methylation of the nephrin promoter in murine glomeruli of an adriamycin nephropathy model with recovery of KLF4 expression and a decrease in albuminuria. In podocyte-specific KLF4 knockout mice, the effect of ARB on albuminuria and the nephrin promoter methylation was attenuated. In cultured human podocytes, angiotensin II reduced KLF4 expression and caused methylation of the nephrin promoter with decreased nephrin expression. In patients, nephrin promoter methylation was increased in proteinuric kidney diseases with decreased KLF4 and nephrin expression. KLF4 expression in ARB-treated patients was higher in patients with than without ARB treatment. Thus, angiotensin II can modulate epigenetic regulation in podocytes and ARB inhibits these actions in part via KLF4 in proteinuric kidney diseases. This study provides a new concept that renin-angiotensin system blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression.

KW - angiotensin

KW - chronic kidney disease

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84942989817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942989817&partnerID=8YFLogxK

U2 - 10.1038/ki.2015.178

DO - 10.1038/ki.2015.178

M3 - Article

C2 - 26108068

AN - SCOPUS:84942989817

VL - 88

SP - 745

EP - 753

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -